FDA Approves Gardasil for Prevention of Cervical Cancer other HPV-related Diseases
Gardasil is a recombinant vaccine indicated for the prevention of cervical cancer, cervical pre-cancers, vulvar pre-cancers and vaginal pre-cancers caused by HPV types 16 and 18. Gardasil is also approved for the prevention of genital warts and low-grade cervical lesions caused by HPV types 6, 11, 16 and 18. Gardasil is approved for 9- to 26-year-old girls and women.Posted: June 2006
Related articles
- FDA: Gardasil Approved to Prevent Anal Cancer - December 22, 2010
- FDA Approves Gardasil for Use in Boys and Young Men - October 16, 2009
- FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers - September 15, 2008
- FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of Gardasil - May 18, 2006
- Gardasil, Merck's Investigational Cervical Cancer Vaccine, to Receive Priority Review from the U.S. Food and Drug Administration - February 7, 2006
- Biologics License Application for Gardasil, Merck's Investigational Cervical Cancer Vaccine, Is On Track - February 2, 2006
- Merck Submits Biologics License Application to FDA for Gardasil, the Company's Investigational Vaccine for Cervical Cancer - December 5, 2005
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
